12.71 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||12.69 x 1200|
|Ask||13.18 x 1000|
|Day's Range||12.54 - 13.48|
|52 Week Range||5.42 - 15.08|
|PE Ratio (TTM)||43.83|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.00|
Johnson & Johnson (JNJ) has been ordered to pay $4.69 billion in damages to 22 families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.
Jazz Pharmaceuticals (JAZZ) signs a definitive contract to sell its Prialt rights to TerSera Therapeutics for a settled amount of $80 million in cash upon its closure.
Zacks.com featured highlights include: Weight Watchers, Johnson Outdoors, ChemoCentryx, Harte-Hanks and IEC
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
ChemoCentryx, 58.com, Seagate, Garmin and Texas Instruments as Zacks Bull and Bear of the Day
Dodging all political ills, investors continued to pour money into the fast-growing companies, pushing the Nasdaq Composite Index to new highs since Mar 13. The surge in the technology sector, which accounts for nearly half of the index, helped the Nasdaq’s northward journey. Notably, the trio of the group — Apple Inc. (NASDAQ:AAPL), Amazon.com, Inc. (NASDAQ:AMZN) and Microsoft Corporation (NASDAQ:MSFT) — set new milestones.
NEW YORK, June 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mitel ...
MOUNTAIN VIEW, Calif., May 30, 2018-- ChemoCentryx, Inc.,, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June:. ...
MOUNTAIN VIEW, Calif., May 23, 2018-- ChemoCentryx, Inc.,, today announced two upcoming presentations during the 55th European Renal Association- European Dialysis and Transplant Association Congress, ...
On a per-share basis, the Mountain View, California-based company said it had a loss of 19 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
--Patient enrollment in Phase III ADVOCATE trial of avacopan in the treatment of ANCA-associated vasculitis exceeds 85%; Conditional Marketing Authorization application under review with European Medicines ...
MOUNTAIN VIEW, Calif., May 02, 2018-- ChemoCentryx, Inc.,, today announced that the Company's first quarter 2018 financial results will be released after market close on Wednesday, May 9, 2018. ChemoCentryx ...
LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free earnings report on ChemoCentryx, Inc. (NASDAQ: CCXI). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CCXI. The Company reported its fourth quarter fiscal 2017 and full fiscal year 2017 operating and financial results on March 14, 2018.
ChemoCentryx Inc (NASDAQ:CCXI) is trading with a trailing P/E of 32.9x, which is higher than the industry average of 27.1x. While CCXI might seem like a stock to avoid orRead More...
ChemoCentryx Inc (NASDAQ:CCXI) delivered an ROE of 22.53% over the past 12 months, which is an impressive feat relative to its industry average of 17.94% during the same period. WhileRead More...